<DOC>
	<DOCNO>NCT01001260</DOCNO>
	<brief_summary>To investigate biosynthesis PGD2 percutaneous transluminal coronary angioplasty ( PTCA ) procedure .</brief_summary>
	<brief_title>PGD2 Formation Vascular Injury</brief_title>
	<detailed_description>A ) To determine whether biosynthesis PGD2 alter response vascular injury human B ) Patients group base aspirin use status . There group aspirin alternative anti-platelet medicine , low dose ( 81 mg ) aspirin , high dose 325 mg aspirin enrol .</detailed_description>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Acute Coronary Syndrome</mesh_term>
	<mesh_term>Angina , Stable</mesh_term>
	<mesh_term>Vascular System Injuries</mesh_term>
	<mesh_term>Aspirin</mesh_term>
	<criteria>Patients exist CAD admit elective PTCA : 1 . Treated dose aspirin daily least 5 day , special interest treat 81 mg aspirin daily 2 . Treated alternative antiplatelet therapy , clopidogrel , due aspirin hypersensitivity PMDs preference 3 . No aspirin therapy Patients present ER Acute Coronary Syndrome ( ACS ) PTCA Patients stable angina positive stress test schedule cardiac catheterization History unstable diabetes ( hgb A1c &gt; 8 FBS &gt; 200 ) Uncontrolled hypertension ( SBP &gt; 180 , DBP &gt; 100 ) History acute confound disease judge clinical screen accord investigator may interfere interpretation study result , compromise safety potential subject . Patients take NSAIDS COX2 inhibitor aspirin , least 10 day prior PTCA</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2011</verification_date>
	<keyword>Prostaglandins</keyword>
	<keyword>vascular injury</keyword>
</DOC>